GSK Changes Potiga Label In Response To Eye, Skin Issues
GlaxoSmithKline PLC said Monday it was in the process of changing the labeling for its anti-seizure drug Potiga, after the U.S. Food and Drug Administration warned the product may lead to...To view the full article, register now.
Already a subscriber? Click here to view full article